張軍

發布時間:2011-08-04         瀏覽次數:8523


  Jun Zhang 張軍(教授博導)

  Professor Jun Zhang got his Bachelor degree on Medicine in 1994 inShanghai Medical School, and then he received three years’ training onepidemiology and was awarded with master degree in 1997. After then he workedin Xiamen University as faculty until now. In 2005, he and his colleaguesfounded National Institute of Diagnostics and Vaccine Development in infectiousdiseases (NIDVD) in Xiamen University. His researches focus on the virology,immunology and epidemiology of many human pathogens. As one of the leadingscientists, he is deeply involved in the innovation and translation of therecombinant hepatitis E vaccine, the recombinant HPV 16/18 bivalent vaccine,the recombinant HPV 6/11 bivalent vaccine and many immunologic diagnosticreagents against infectious pathogens. Among them, the Hepatitis E vaccine hasbeen commercially launched in China in 2012; the HPV16/18 vaccine and HPV 6/11vaccine are under Phase III and Phase I clinical trials in China, respectively;more than 40 kinds of immunodiagnostic kits for infectious disease such asAIDS, tuberculosis, hepatitis, influenza, foot and mouth disease had beenmarketed in China. He had published > 60 papers in peer reviewed journals.

 1994年上海醫科大學醫學學士(預防醫學專業)、1997年上海醫科大學醫學碩士(流行病學專業)。1997年至今任職于廈門大學,2006年晉升教授,2008年起擔任博士生導師,現任廈門大學威尼斯人官方網址副院長、國家傳染病診斷試劑與疫苗工程技術研究中心副主任。2005年入選教育部新世紀優秀人才;2008年獲“中國十大杰出青年”提名獎;2010年獲“中國青年五四獎章”;2011年獲第十二屆中國青年科技獎;2012年入選科技部首批中青年科技創新領軍人才,2014年入選中組部“萬人計劃”第一批科技創新領軍人才、福建省委組織部首批特支計劃“雙百人才”、福建省百千萬人才工程。中華醫學會微免分會第八屆青年委員會副主任委員,全國專業計量技術委員會委員。

長期從事體外診斷試劑、疫苗研究,先后在《新英格蘭醫學雜志》、《柳葉刀》等國際學術刊物發表論文90余篇,獲得國內外發明專利授權二十余項。參與研制出世界上第一個戊型肝炎疫苗和40余種體外診斷試劑并均已上市銷售,研制的國內第一個宮頸癌疫苗正在進行三期臨床試驗。先后主持863計劃重大項目等國家級重大重點科研項目十余項。先后獲國家科技進步二等獎(2001,第2完成人)、國家技術發明二等獎(2010,第4完成人)、教育部提名國家科技進步二等獎(第1完成人)等科技獎勵。


Selected Publication:

1.Jun Zhang*#, Xue-Feng Zhang#, Shou-Jie Huang, Ting Wu, Yue-Mei Hu,Zhong-Ze Wang, Hua Wang, Han-Min Jiang, Yi-Jun Wang, Qiang Yan, Meng Guo, Xiao-HuiLiu, Jing-Xin Li, Chang-Lin Yang, Quan Tang, Ren-Jie Jiang, Hui-Rong Pan,Yi-Min Li, J. Wai-Kuo Shih, Mun-Hon Ng, Feng-Cai Zhu, Ning-Shao Xia*.Longer-Term Efficacy of a Vaccine against Hepatitis E. New Engl J Med2015;372(10):914-22. (#:共第一作者,*:共通訊作者) IF= 54.420

2.Zhu FC#,Zhang J#, ZhangXF, Zhou C, Wang ZZ, Huang SJ, Wang H, Yang CL, Jiang HM, Cai JP, Wang YJ, AiX, Hu YM, Tang Q, Yao X, Yan Q, Xian YL, Wu T, Li YM, Miao J, Ng MH, Shih JW,Xia NS*. Efficacy and safety of a recombinant hepatitis E vaccine in healthyadults: a large-scale, randomised, double-blind placebo-controlled, phase 3trial. Lancet, 2010, 376(9744): 895–902. (#共第一作者)IF=33.633

3.Quan Yuan, Liu-WeiSong, Chun-Jen Liu, Zhuo Li, Ping-Guo Liu, Cheng-Hao Huang, Yan Yan,Sheng-Xiang Ge, Ying-Bin Wang, Cheng-Yuan Peng, Jun Zhang*, Jia-Horng Kao, Ding-Shinn Chen, Pei-Jer Chen*,Ning-Shao Xia*. Hepatitis B core antibody level may help predict treatmentresponse in chronic hepatitis B patients. Gut, 2013,62(1):182-4.(共通訊作者)(IF=10.614)

4.Huang CH, Yuan Q,Chen PJ, Zhang YL, Chen CR, Zheng QB, Yeh SH, Yu H, Xue Y, Chen YX, Liu PG, GeSX, Zhang J*, Xia NS*.Influence of Mutations in Hepatitis B Virus Surface Protein on ViralAntigenicity and Phenotype in Occult HBV Strains from Blood Donors. JHepatol. 2012,57(4):720-9.共通訊作者(IF=9.334)

5.Zhang J#, Zhang XF#,Zhou C, Wang ZZ, Huang SJ, Yao X, Liang ZL, Wu T, Li JX, Yan Q, Yang CL, JiangHM, Huang HJ, Xian YL, J W-K Shih, M-H Ng, Li YM , Wang JZ*, Zhu FC* and XiaNS*: Protection against hepatitis E virus infection by naturally acquired and vaccine-inducedimmunity. Clin Microbiol Infect2014; 20: O397–O405. #共第一作者(IF= 5.197)

6.Chen S, Zhou Z, Wei FX, Huang SJ, Tan Z,Fang Y, Zhu FC, Wu T*, Zhang J*, Xia NS. Modeling the long-termantibody response of a hepatitis E vaccine. Vaccine. 2015, pii: S0264-410X(15)00839-7. doi:10.1016/j.vaccine.2015.06.050. (IF=3.492)共通訊作者

7.Wu T, Hu YM*, Li J, Chu K, Huang SJ, ZhaoH, Wang ZZ, Yang CL, Jiang HM, Wang YJ, Lin ZJ, Pan HR, Sheng W, Wei FX, Li SW,Wang Y, Zhu FC, Li CG, Zhang J*, Xia NS. Immunogenicity andsafety of an E. coli-produced bivalent human papillomavirus (type 16 and 18)vaccine: A randomized controlled phase 2 clinical trial. Vaccine. 2015, 33(32):3940-6.共通訊作者(IF=3.492)

8.Yue Zhang, Min Li, Fan Yang, Yufang Li,Zizheng Zheng, Xiao Zhang, Qingshan Lin, Ying Wang, Shaowei Li, Ningshao Xia, JunZhang*, and Qinjian Zhao*. Comparable quality attributes of hepatitis E vaccine antigen with andwithout adjuvant adsorption-dissolution treatment. Hum Vaccin Immunother. 2015,11(5): 1129-39共通訊作者)(IF= 2.131

9.Hu YM, Huang SJ, Chu K, Wu T, Wang ZZ,Yang CL, Cai JP, Jiang HM, Wang YJ, Guo M, Liu XH, Huang HJ, Zhu FC, ZhangJ*, Xia NS. Safety of an Escherichia coli-expressed bivalent humanpapillomavirus (types 16 and 18) L1 virus-like particle vaccine: An open-labelphase I clinical trial. Hum VaccinImmunother. 2014;10(2):1-7.通訊作者)(IF= 2.131

10.Yixin Chen, Chuan Li, Delei He, TongCheng, Shengxiang Ge, James Wai-Kuo Shih,Qinjian Zhao, Pei-Jer Chen, JunZhang?, NingshaoXia?, Antigenic analysis of divergentgenotypes human Enterovirus 71 viruses by a panel of neutralizing monoclonalantibodies: Current genotyping of EV71 does not reflect their antigenicity. Vaccine 2013, 31:425-430 (共通訊作者) (IF=3.492)

11.Zhang J, Shih JW*, Wu T, Li SW, Xia NS: Development of the hepatitis E vaccine:from bench to field. Sem Liver Dis2013, 33(1):79-88. (IF=8.274)

12.Zhang J, Li SW, Wu T, Zhao Q, Ng MH, Xia NS. HepatitisE virus: neutralizing sites, diagnosis,and protective immunity. Rev Med Virol.2012,22(5):339-49.(IF=7.615)

13.Huang SJ, ZhangXF, Jiang HM, Yan Q, Ai X, Wang YJ, Cai JP, Jiang L, Wu T, Wang ZZ, Guan L,Shih JWK, Ng MH, Zhu FC, Zhang J*,Xia NS. Profile of Acute Infectious Markers in Sporadic Hepatitis E. PLoSOne. 2010, 5(10): e13560.通訊作者(IF=4.411)

14.Yu H, Yuan Q, GeSX, Wang HY, Zhang YL, Chen QR, ZhangJ*, Chen PJ, Xia NS. Molecular and phylogenetic Analyses Suggest anAdditional Hepatitis B Virus Genotype “I”, PLoS One. 2010, 5(2):e9297.通訊作者(IF=4.411)

15.Yuan Q, Ou SH,Chen CR*, Ge SX, Pei B, Chen QR, Yan Q, Lin YC, Ni HY, Huang CH, Yeo AET, ShihJWK, Zhang J*, Xia NS.Molecular Characteristics of Occult Hepatitis B Virus from Blood Donors inSoutheast China, J Clin Microbiol, 2010, 48: 357–362. 共通訊作者)(IF=4.220

16.Zhu FC, Huang SJ,Wu T, Zhang XF, Wang ZZ, Ai X, Yan Q, Yang CL, Cai JP, Jiang HM, Wang YJ,Mun-Hon Ng, Zhang J *, XiaNS. Epidemiology of Zoonotic Hepatitis E: A Community-Based Surveillance Studyin a Rural Population in China. PLoS One, 2014, 9(1): e87154 通訊作者)(IF=3.534

17.Li A, Yuan Q,Huang ZY, Fan J, Guo RY, Lou B, Zheng Q, Ge SX*, Chen YX, Su ZJ, Yeo AET, ChenY, Zhang J*, Xia NS. NovelDouble-Antigen Sandwich Immunoassay for Human Hepatitis B Core Antibody. ClinVac Immunol 2010,17:464–469.共通訊作者)(IF =2.471

18.Yuan Q, Ge SX,Xiong JH, Yan Q, Li Z, Hao XK, Tian DY, Niu JJ, Su ZJ, Chen CR, Shih JWK, Zhang J?,Xia NS. A novel immunoassay for PreS1 and/or core-related antigens fordetection of HBsAg variants. J Virol Methods.2010;168(1-2):108-113.通訊作者)(IF =2.139

19.Zhang J, Liu CB, Li RC, LiYM, Zheng YJ, Li YP, Luo D, Pan BB, Nong Y, Ge SX, Xiong JH, Shih JW, Ng MH,Xia NS. (2009) Randomized-controlled phase II clinical trial of a bacteriallyexpressed recombinant hepatitis E vaccine. Vaccine, 27:1869-1874 (IF =3.377)

20.Wu T., Wu X.L., OuS.H., Lin C.X., Cheng T., Li S.W., Ng M.H., Zhang J.,*XiaN.S.*, Difference of T cell and B cell activation in two homologousproteins with similar antigenicity but great distinct immunogenicity. MolImmunol, 2007, 44(12): 3261-3266(IF =3.742)共通訊作者

21.Zhang J, Gu Y, Ge SX, LiSW, He ZQ, Huang GY, Zhuang H, Ng MH, Xia NS. Analysis of hepatitis E virusneutralization sites using monoclonal antibodies directed against a viruscapsid protein. Vaccine 2005;23:2881-2892 (IF =3.377)

22.Zhang J, Ge SX, Huang GY,Li SW, He ZQ, Wang YB, Zheng YJ, Gu Y, Ng MH, Xia NS. Evaluation ofantibody-based and nucleic acid-based assays for diagnosis of hepatitis E virusinfection in a rhesus monkey model. J Med Virol 2003;71:518-526  (IF =2.471).